GSK
HEALTHCAREGSK Plc
$50.53+0.15 (+0.30%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving GSK Today?
No stock-specific AI insight has been generated for GSK yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$34.48$61.21
$50.53
Fundamentals
Market Cap$101.4B
P/E Ratio13.1
EPS$3.86
Dividend Yield0.03%
Dividend / Share$0.67
ROE0.4%
Profit Margin0.2%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding2.01B
GSK News
33 articles- Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adultsYahoo Finance·May 7, 2026
- Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical SummitYahoo Finance·May 6, 2026
- GSK's (LON:GSK) Performance Is Even Better Than Its Earnings SuggestYahoo Finance·May 6, 2026
- Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence GenerationYahoo Finance·May 5, 2026
- SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackYahoo Finance·May 4, 2026
- European Equities Traded in the US as American Depositary Receipts Start Week LowerYahoo Finance·May 4, 2026
- A Look At GSK (LSE:GSK) Valuation After Recent Share Price Weakness And Pipeline DevelopmentsYahoo Finance·May 3, 2026
- GSK (GSK) Completes $950M Acquisition to Expand Drug PipelineYahoo Finance·May 3, 2026
- GSK Juggles Alzheimer’s Setback And Leadership Shift With Product ProgressYahoo Finance·May 3, 2026
- Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?Yahoo Finance·May 1, 2026
- IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 ViewYahoo Finance·Apr 30, 2026
- Why GSK (GSK) is a Top Value Stock for the Long-TermYahoo Finance·Apr 30, 2026
- JP Morgan retains 'underweight' on GSK with £17 price target as earnings upgrade potential seen as limitedProactive Investors·Apr 30, 2026
- GSK PLC (GSK) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Pipeline ExpansionYahoo Finance·Apr 30, 2026
- European Equities Traded in the US as American Depositary Receipts Lower in Wednesday TradingYahoo Finance·Apr 29, 2026
- GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales GrowthYahoo Finance·Apr 29, 2026
- Is GSK (LSE:GSK) Pricing Its Strong Multi Year Share Gains Fairly TodayYahoo Finance·Apr 29, 2026
- Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Policy DecisionYahoo Finance·Apr 29, 2026
- GSK Q1 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- GSK (GSK) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 29, 2026
- Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor IntelligenceGlobeNewswire Inc.·Apr 28, 2026
- Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach ClaimGlobeNewswire Inc.·Apr 24, 2026
- Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc.·Apr 24, 2026
- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- ENA Respiratory Appoints Melissa Faris to BoardGlobeNewswire Inc.·Apr 23, 2026
- 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc.·Apr 10, 2026
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightGlobeNewswire Inc.·Apr 7, 2026
- From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation BlockerBenzinga·Apr 7, 2026
- Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a DimeInvesting.com·Apr 6, 2026
- Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: ReportBenzinga·Apr 2, 2026
- SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)Benzinga·Mar 31, 2026
- Sitryx to participate in upcoming April investor conferencesGlobeNewswire Inc.·Mar 26, 2026
All 33 articles loaded
Price Data
Open$51.09
Previous Close$50.38
Day High$51.22
Day Low$50.52
52 Week High$61.21
52 Week Low$34.48
52-Week Range
$34.48$61.21
$50.53
Fundamentals
Market Cap$101.4B
P/E Ratio13.1
EPS$3.86
Dividend Yield0.03%
Dividend / Share$0.67
ROE0.4%
Profit Margin0.2%
Debt / Equity—
Trading
Volume3.9M
Avg Volume (10D)—
Shares Outstanding2.01B
About GSK Plc
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
HEALTHCAREDRUG MANUFACTURERS - GENERAL
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - GENERAL
CIK—
Composite FIGI—
Share Class FIGI—